4 December 2018 - PhD Studentship Opportunity with the Uni. of Hertfordshire

Neurolixis is pleased to announce a PhD Studentship Opportunity in collaboration with the University of Hertforshire (UK). The successful candidate will investigate the therapeutic potential of novel compounds (notably NLX-112) developed by Neurolixis. These compounds target serotonergic mechanisms which are involved in the neurobiology of Parkinson's disease and of neuroprotective functions. The project will provide training in a range of in vitro and in vivo techniques relevant to modern neuropharmacology including animal behavioral paradigms, neural circuitry relevant to Parkinson's disease and modern biochemical techniques.

The four-year project will start in early 2019 and includes a stipend of £14,777 per annum plus approved expenses.
For more information, or to submit an application, see the University of Hertforshire announcement here.

25 July 2018 - Just Published: PET and fMRI imaging on NLX-112 and NLX-101

An innovative brain imaging study combined Positron Emission Tomography (PET) and functional Magnetic Resonance Imaging (fMRI) to characterize the labeling and functional connectivity of NLX-112 and NLX-101. Both compounds are highly selective for serotonin 5-HT1A receptors but exhibit preferential interaction (or 'biased agonism') at specific receptor sub-populations. NLX-112 is being developed for treatment of dyskinesia in Parkinson's disease, whereas NLX-101 is a candidate for treatment of Rett syndrome. The imaging study was carried out at the Lyon Neuroscience Research Center (France) by the team of Prof. Luc Zimmer, with whom Neurolixis has a long-standing collaboration.


In vivo biased agonism at 5-HT1A receptors: characterisation by simultaneous PET/MR imaging.

Vidal B, Fieux S, Redouté J, Villien M, Bonnefoi F, Le Bars D, Newman-Tancredi A, Costes N, Zimmer L.
Neuropsychopharmacology. 2018 Jul 6. doi: 10.1038/s41386-018-0145-2. PMID: 30030540